MC
EDIT icon

Moors & Cabot’s Editas Medicine EDIT Stock Holding History

Moors & Cabot’s Portfolio EDIT Stock Details EDIT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-10,007
Closed -$88.8K – 894
2022
Q4 		$88.8K Buy
+10,007
New +$110K 0.01% 803
2021
Q4 		– Sell
-5,201
Closed -$214K – 923
2021
Q3 		$214K Buy
5,201
+1,250
+32% +$68.5K 0.01% 732
2021
Q2 		$224K Buy
+3,951
New +$146K 0.02% 688

Other funds holding EDIT

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Moors & Cabot's EDIT Position: Q1 2023 in Review

Moors & Cabot sold out of Editas Medicine (EDIT) in Q1 2023, closing a stake of 10,007 shares — an estimated $88.8K sold.

Moors & Cabot first reported a position in EDIT in Q2 2021 and held it in 3 quarters. The position peaked at $224K in Q2 2021. 234 funds tracked by Wall St. Rank hold EDIT as of Q1 2023.

  • Moors & Cabot reported no remaining Editas Medicine position as of Q1 2023 after selling out during the quarter.
  • Moors & Cabot sold 10,007 Editas Medicine shares in Q1 2023, an estimated $88.8K.
  • Moors & Cabot first reported a position in Editas Medicine in Q2 2021 and held it in 3 quarters.
  • Moors & Cabot's Editas Medicine position peaked at $224K in Q2 2021.
  • 234 funds tracked by Wall St. Rank held Editas Medicine as of Q1 2023.

Based on Moors & Cabot's 13F filing for Q1 2023, filed 5 May 2023.